The disease-specific arm of the therapeutic effect of intravenous immunoglobulin in autoimmune diseases: Experimental autoimmune myasthenia gravis as a model

Israel Medical Association Journal

Volumn 10, Issue 1, 2008, Pages 58-60

  Fuchs, Sara ^a   Feferman, Tali ^a   Meidler, Roberto ^b   Brenner, Talma ^c   Laub, Orgad ^b   Souroujon, Miriam C ^a,d  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b Omrix Biopharmaceuticals   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d OPEN UNIVERSITY OF ISRAEL   (Israel)

Author keywords

Experimental autoimmune myasthenia gravis; Fractionation; Immunotherapy; Intravenous immunoglobulin; Myasthenia gravis

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL PROLIFERATION; CHROMATOGRAPHY; CONTROLLED STUDY; DISEASE MODEL; ELUTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; MYASTHENIA GRAVIS; NONHUMAN; OUTCOME ASSESSMENT; RAT; TH1 CELL; TREATMENT OUTCOME; ANIMAL; DRUG EFFECT; FRACTIONATION;

ANIMALS; B-LYMPHOCYTES; CELL PROLIFERATION; CHEMICAL FRACTIONATION; CHROMATOGRAPHY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; RATS; TH1 CELLS;

EID: 41149112944     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat Clin Pract Rheumatol 2007;3:262-72.
2. Gold R, Stangel M, Dalakas MC. Drug Insight: the use of intravenous immunoglobulin in neurology - therapeutic considerations and practical issues. Nat Clin Pract Neurol 2007;3:36-44.
3. Zhu KY, Feferman T, Maiti PK, Souroujon MC, Fuchs S. Intravenous immunoglobulin suppresses experimental myasthenia gravis: immunological mechanisms. J Neuroimmunol 2006;176:187-97.
4. Fuchs S, Feferman T, Meidler R, et al. A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis. J Neuroimmunol 2008. (In press).
5. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291:484-6.
6. Achiron A, Mor F, Margalit R, Cohen IR, Lider O, Miron S. Suppression of experimental autoimmune encephalomyelitis by intravenously administered polyclonal immunoglobulins. J Autoimmun 2000;15:323-30.
7. Jorgensen SH, Sorensen PS. Intravenous immunonoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. J Neurol Sci 2005;233:61-5.
8. Pashov A, Dubey C, Kaveri SV, et al. Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein. Eur J Immunol 1998;28:1823-31.
9. Weishaupt A, Kuhlmann T, Schonrock, LM, Toyka KV, Bruck W, Gold R. Effects of intravenous immunoglobulins on T cell and oligodendrocyte apoptosis in high-dose antigen therapy in experimental autoimmune encephalomyelitis. Acta Neuropathol (Berl) 2002;104:385-90.
10. Saoudi A, Hurez V, de Kozak Y. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol 1993;5:1559-67.
11. Wada J, Shintani N, Kikutani K, Nakae T. Yamauchi T, Takechi K. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition. Clin Exp Immunol 2001;124:282-9.
12. Jia J, Pollock M. Treatment of rats with experimental allergic neuritis using high dose immunoglobulin. Chin Med J (Engl) 2000;113: 1096-9.
13. Shoenfeld Y, Rauova L, Gilburd B, et al. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 2002;14:1303-11.
14. Souroujon MC, Barchan D, Fuchs S. Analysis and modulation of the immune response of mice to acetylcholine receptor by antiidiotypes. Immunol Lett 1985;9:331-6.
15. Souroujon MC, Fuchs S. Idiotypes and anti-idiotypes in experimental autoimmune myasthenia gravis. Ann N Y Acad Sci 1986;475:81-93.
16. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004;102:177-93.
17. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of im2munoglobulin G resulting from Fc sialylation. Science 2006; 313:670-3.